Hongrui Zhu

Dr. Hongrui Zhu


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2023 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
HZHongrui Zhu
Hongrui Zhu
AGAo Guan
Ao Guan
JLJiayuan Liu
Jiayuan Liu
LPLi Peng
Li Peng
ZZZhi Zhang
Zhi Zhang
SWSheng Wang
Sheng Wang
Microglia are so versatile that they not only provide immune surveillance for central nervous system, but participate in neural circuitry development, brain blood vessels formation, blood–brain barrier architecture, and intriguingly, the regulation of emotions and behaviors. Microglia have a profound impact on neuronal survival, brain wiring and synaptic plasticity. As professional phagocytic cells in the brain, they remove dead cell debris and neurotoxic agents via an elaborate mechanism. The functional profile of microglia varies considerately depending on age, gender, disease context and other internal or external environmental factors. Numerous studies have demonstrated a pivotal involvement of microglia in neuropsychiatric disorders, including negative affection, social deficit, compulsive behavior, fear memory, pain and other symptoms associated with major depression disorder, anxiety disorder, autism spectrum disorder and schizophrenia. In this review, we summarized the latest discoveries regarding microglial ontogeny, cell subtypes or state spectrum, biological functions and mechanistic underpinnings of emotional and behavioral disorders. Furthermore, we highlight the potential of microglia-targeted therapies of neuropsychiatric disorders, and propose outstanding questions to be addressed in future research of human microglia.

4 February 2019 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
MSMin Sun
Min Sun
DWDi Wu
Di Wu
KZKe Zhou
Ke Zhou
HLHeng Li
Heng Li
XGXingrui Gong
Xingrui Gong
DHDong Huang
Dong Huang

13 March 2019 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
MSMin Sun
Min Sun
MDMengyu Du
Mengyu Du
WZWenhua Zhang
Wenhua Zhang
SXSisi Xiong
Sisi Xiong
XGXingrui Gong
Xingrui Gong
XGXinsheng Gu
Xinsheng Gu
Background: Silent information regulator 2 homolog 1 (SIRT1) is an evolutionarily conserved enzymes with nicotinamide adenine dinucleotide (NAD)+-dependent deacetylase activity. SIRT1 is involved in a large variety of cellular processes, such as genomic stability, energy metabolism, senescence, gene transcription, and oxidative stress. SIRT1 has long been recognized as both a tumor promoter and tumor suppressor. Its prognostic role in cancers remains controversial. Methods: A meta-analysis of 13,138 subjects in 63 articles from PubMed, EMBASE, and Cochrane Library was performed to evaluate survival and clinicopathological significance of SIRT1 expression in various cancers. Results: The pooled results of meta-analysis showed that elevated expression of SIRT1 implies a poor overall survival (OS) of cancer patients [Hazard Ratio (HR) = 1.566, 95% CI: 1.293–1.895, P < 0.0001], disease free survival (DFS) (HR = 1.631, 95% CI: 1.250–2.130, P = 0.0003), event free survival (EFS) (HR = 2.534, 95% CI: 1.602–4.009, P = 0.0001), and progress-free survival (PFS) (HR = 3.325 95% CI: 2.762–4.003, P < 0.0001). Elevated SIRT1 level was associated with tumor stage [Relative Risk (RR) = 1.299, 95% CI: 1.114–1.514, P = 0.0008], lymph node metastasis (RR = 1.172, 95% CI: 1.010–1.360, P = 0.0363), and distant metastasis (RR = 1.562, 95% CI: 1.022–2.387, P = 0.0392). Meta-regression and subgroup analysis revealed that ethnic background has influence on the role of SIRT1 expression in predicting survival and clinicopathological characteristics of cancers. Overexpression of SIRT1 predicted a worse OS and higher TNM stage and lymphatic metastasis in Asian population especially in China. Conclusion: Our data suggested that elevated expression of SIRT1 predicted a poor OS, DFS, EFS, PFS, but not for recurrence-free survival (RFS) and cancer-specific survival (CCS). SIRT1 overexpression was associated with higher tumor stage, lymph node metastasis, and distant metastasis. SIRT1-mediated molecular events and biological processes could be an underlying mechanism for metastasis and SIRT1 is a therapeutic target for inhibiting metastasis, leading to good prognosis.

1 February 2024 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
JLJun Li
Jun Li
HZHongrui Zhu
Hongrui Zhu
YWYu Wang
Yu Wang
JCJiaqi Chen
Jiaqi Chen
KHKeqiang He
Keqiang He
SWSheng Wang
Sheng Wang
Background: Emergence agitation (EA) is one of the most common complications in clinical general anesthesia during recovery in adults. Remifentanil and propofol can reduce the incidence of EA, but with no randomized controlled trial to evaluate their effectiveness for treating EA. This study aims to compare the effectiveness of remifentanil and propofol for treating EA following general anesthesia. Patients and methods: Among 152 randomized patients with a mean of 49.5 years, and 99 (65.1%) of them being male, 149 were divided into two groups for subsequent analysis. The remifentanil group (Group R, n = 74) received a 0.5μg kg– 1 remifentanil infusion followed by a 0.05μg kg– 1 min– 1 infusion until 15 minutes, after the onset of agitation. The propofol group (Group P, n = 75) received a 1mg kg– 1 propofol infusion once agitation occurred. Emergence agitation was assessed using the Riker Sedation Agitation Score, with a score of ≥ 5 defining emergence agitation. During the post–anesthesia care unit (PACU), the recurrence of emergence agitation, time to extubation, and discharge from PACU were evaluated. Results: The incidence of reoccurring emergence agitation was lower in Group R (29.7%) compared with Group P (49.3%), with an odds ratio of 0.44 (95% CI 0.22– 0.85; P=0.014). The time to extubation was shorter in Group R (mean 12min, range 8– 15 min) compared with Group P (mean 17min, range 13– 21 min) (P< 0.001), as was the time discharge from the PACU (mean 30.5 min, range 25– 40 min) vs Group P (mean 37.5 min, range 31– 50 min) (P=0.001). Conclusion: Treatment of emergence agitation in adults with remifentanil infusion is more effective than propofol, with a shorter time to extubation and discharge from PACU.

13 March 2024 in Journal of Molecular Neuroscience
Verified
Journal Article
Closed access
PDF file
JLJiayuan Liu
Jiayuan Liu
LPLi Peng
Li Peng
LHLingwei He
Lingwei He
TYTianyue Yin
Tianyue Yin
YDYuhao Du
Yuhao Du
SWSheng Wang
Sheng Wang

28 July 2024 in Experimental Neurology
Verified
Journal Article
Open access
MYMengmeng Yang
Mengmeng Yang
HZHongrui Zhu
Hongrui Zhu
LPLi Peng
Li Peng
TYTianyue Yin
Tianyue Yin
SSShuaijie Sun
Shuaijie Sun
SWSheng Wang
Sheng Wang
Post-stroke anxiety (PSA) seriously affects the prognosis of patients, which is an urgent clinical problem to be addressed. However, the pathological mechanism of PSA is largely unclear. Here, we found that neuronal HIPK2 expression was upregulated in the ischemic lesion after stroke. The upregulation of HIPK2 promotes Drp1 oligomerization through the HDAC3-dependent pathway, leading to excessive mitochondrial damage. This subsequently triggers the release of cellular cytokines such as IL-18 from neurons under ischemic stress. Microglia are capable of responding to IL-18, which promotes their activation and enhances their phagocytosis, ultimately resulting in the loss of synapses and neurons, thereby exacerbating the pathological progression of PSA. HIPK2 knockdown or inhibition suppresses excessive pruning of neuronal synapses by activated microglia in the contralateral vCA1 region to compromise inactivated anxiolytic pBLA-vCA1Calb1+ circuit, relieving anxiety-like behavior after stroke. Furthermore, we discovered that early remimazolam administration can remodel HIPK2-HDAC3 axis, ameliorating the progression of PSA. In conclusion, our study revealed that the neuronal HIPK2-HDAC3 axis in the ischemic focus regulates mitochondrial fragmentation to balance inflammation stress reservoir to participate in anxiety susceptibility after stroke.